extended half-life factor IX
GPTKB entity
Statements (19)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:benefit |
reduced infusion frequency
|
| gptkbp:category |
gptkb:anticoagulant
orphan drug |
| gptkbp:example |
albutrepenonacog alfa
eftrenonacog alfa nonacog beta pegol |
| gptkbp:form |
gptkb:protein
recombinant factor IX PEGylated factor IX |
| https://www.w3.org/2000/01/rdf-schema#label |
extended half-life factor IX
|
| gptkbp:mechanismOfAction |
replaces missing or deficient factor IX
|
| gptkbp:regulates |
approved by FDA
approved by EMA |
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:targetAudience |
patients with hemophilia B
|
| gptkbp:usedFor |
gptkb:hemophilia_B
|
| gptkbp:bfsParent |
gptkb:factor_IX
|
| gptkbp:bfsLayer |
6
|